{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:10:51Z","timestamp":1793297451687,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006470","name":"Aristotle University of Thessaloniki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims\/hypothesis<\/jats:title>\n                <jats:p>We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA<jats:sub>1c<\/jats:sub> and body weight from baseline. Secondary outcomes were achievement of HbA<jats:sub>1c<\/jats:sub> target of \u226448 mmol\/mol (\u22646.5%) or &lt;53 mmol\/mol (&lt;7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA<jats:sub>1c<\/jats:sub> (mean difference \u221221.61 mmol\/mol [\u22121.96%]) followed by tirzepatide 10 mg (\u221220.19 mmol\/mol [\u22121.84%]), semaglutide 2.0 mg (\u221217.74 mmol\/mol [\u22121.59%]), tirzepatide 5 mg (\u221217.60 mmol\/mol [\u22121.60%]), semaglutide 1.0 mg (\u221215.25 mmol\/mol [\u22121.39%]) and semaglutide 0.5 mg (\u221212.00 mmol\/mol [\u22121.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions\/interpretation<\/jats:title>\n                <jats:p>Our data show that s.c. tirzepatide had a more pronounced effect on HbA<jats:sub>1c<\/jats:sub> and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Registration<\/jats:title>\n                <jats:p>PROSPERO registration no. CRD42022382594<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00125-024-06144-1","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T06:01:45Z","timestamp":1712988105000},"page":"1206-1222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-0574","authenticated-orcid":false,"given":"Thomas","family":"Karagiannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5134-2401","authenticated-orcid":false,"given":"Konstantinos","family":"Malandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-1342","authenticated-orcid":false,"given":"Ioannis","family":"Avgerinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-2350","authenticated-orcid":false,"given":"Athina","family":"Stamati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-9819","authenticated-orcid":false,"given":"Panagiota","family":"Kakotrichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-2979","authenticated-orcid":false,"given":"Aris","family":"Liakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6701-0712","authenticated-orcid":false,"given":"Despoina","family":"Vasilakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-1803","authenticated-orcid":false,"given":"Nikolaos","family":"Kakaletsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-4072","authenticated-orcid":false,"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-3835","authenticated-orcid":false,"given":"Eleni","family":"Bekiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"issue":"4","key":"6144_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 173(4):278\u2013287. https:\/\/doi.org\/10.7326\/M20-0864","journal-title":"Ann Intern Med"},{"issue":"9","key":"6144_CR2","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/DOM.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116\u20132124. https:\/\/doi.org\/10.1111\/DOM.14451","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"6144_CR3","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/S00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A et al (2022) Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65(8):1251\u20131261. https:\/\/doi.org\/10.1007\/S00125-022-05715-4","journal-title":"Diabetologia"},{"issue":"12","key":"6144_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/S00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925\u20131966. https:\/\/doi.org\/10.1007\/S00125-022-05787-2","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"6144_CR5","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/DC24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care 47(Suppl 1):S158\u2013S178. https:\/\/doi.org\/10.2337\/DC24-S009","journal-title":"Diabetes Care"},{"key":"6144_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385:503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"issue":"6","key":"6144_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH et al (2022) Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 10(6):418\u2013429. https:\/\/doi.org\/10.1016\/S2213-8587(22)00085-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6144_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/S11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T (2017) Network meta-analysis: an introduction for clinicians. Intern Emerg Med 12(1):103\u2013111. https:\/\/doi.org\/10.1007\/S11739-016-1583-7","journal-title":"Intern Emerg Med"},{"issue":"1","key":"6144_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/S13643-018-0699-4","volume":"7","author":"MJ Page","year":"2018","unstructured":"Page MJ, Shamseer L, Tricco AC (2018) Registration of systematic reviews in PROSPERO: 30,000 records and counting. Syst Rev 7(1):32. https:\/\/doi.org\/10.1186\/S13643-018-0699-4","journal-title":"Syst Rev"},{"issue":"11","key":"6144_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"6144_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.JCLINEPI.2020.01.008","volume":"121","author":"J Clark","year":"2020","unstructured":"Clark J, Glasziou P, Del Mar C, Bannach-Brown A, Stehlik P, Scott AM (2020) A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol 121:81\u201390. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2020.01.008","journal-title":"J Clin Epidemiol"},{"key":"6144_CR12","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/BMJ.L4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/BMJ.L4898","journal-title":"BMJ"},{"issue":"2","key":"6144_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/JRSM.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G (2012) Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 3(2):161\u2013176. https:\/\/doi.org\/10.1002\/JRSM.57","journal-title":"Res Synth Methods"},{"issue":"2","key":"6144_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JPT, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159(2):130\u2013137. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008","journal-title":"Ann Intern Med"},{"issue":"4","key":"6144_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/JRSM.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3(4):312\u2013324. https:\/\/doi.org\/10.1002\/JRSM.1058","journal-title":"Res Synth Methods"},{"issue":"7804","key":"6144_CR16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/BMJ.D549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ (2011) Interpretation of random effects meta-analyses. BMJ 342(7804):964\u2013967. https:\/\/doi.org\/10.1136\/BMJ.D549","journal-title":"BMJ"},{"issue":"1","key":"6144_CR17","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1002\/CL2.1080","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G (2020) CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev 16(1):e1080. https:\/\/doi.org\/10.1002\/CL2.1080","journal-title":"Campbell Syst Rev"},{"issue":"3","key":"6144_CR18","doi-asserted-by":"publisher","first-page":"e00750","DOI":"10.1002\/PRP2.750","volume":"9","author":"M Dankers","year":"2021","unstructured":"Dankers M, Nelissen-Vrancken MHJMG, Hart BH, Lambooij AC, van Dijk L, Mantel-Teeuwisse AK (2021) Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals\u2019 preferences. Pharmacol Res Perspect 9(3):e00750. https:\/\/doi.org\/10.1002\/PRP2.750","journal-title":"Pharmacol Res Perspect"},{"issue":"7\u20138","key":"6144_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/SIM.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29(7\u20138):932\u2013944. https:\/\/doi.org\/10.1002\/SIM.3767","journal-title":"Stat Med"},{"issue":"2","key":"6144_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/JRSM.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98\u2013110. https:\/\/doi.org\/10.1002\/JRSM.1044","journal-title":"Res Synth Methods"},{"issue":"1","key":"6144_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/S12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15(1):58. https:\/\/doi.org\/10.1186\/S12874-015-0060-8","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"6144_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/JSS.V106.I02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A et al (2023) netmeta: an R Package for network meta-analysis using frequentist methods. J Stat Softw 106(2):1\u201340. https:\/\/doi.org\/10.18637\/JSS.V106.I02","journal-title":"J Stat Softw"},{"key":"6144_CR23","unstructured":"Chaimani A, Yu T (2023) A hands-on introduction to NMAstudio: a web-application to produce and visualize network meta-analyses. Abstracts accepted for the 27th Cochrane Colloquium, London, UK. Cochrane Database of Systematic Reviews 2023; (1 Supp 1):36690 (Abstract)"},{"key":"6144_CR24","unstructured":"NMAstudio (2020) Welcome to NMAstudio 2.0. Available from www.nmastudioapp.com\/. Accessed: 19 November 2023"},{"issue":"4","key":"6144_CR25","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/JOURNAL.PMED.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T et al (2020) CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17(4):e1003082. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1003082","journal-title":"PLoS Med"},{"issue":"4","key":"6144_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima S-I, Tsoukas GM et al (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5(4):251\u2013260. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6144_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5(5):341\u2013354. https:\/\/doi.org\/10.1016\/S2213-8587(17)30092-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6144_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G et al (2018) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 41(2):258\u2013266. https:\/\/doi.org\/10.2337\/dc17-0417","journal-title":"Diabetes Care"},{"issue":"5","key":"6144_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5(5):355\u2013366. https:\/\/doi.org\/10.1016\/S2213-8587(17)30085-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6144_CR30","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"H Rodbard","year":"2018","unstructured":"Rodbard H, Lingvay I, Reed J et al (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 103(6):2291\u20132301. https:\/\/doi.org\/10.1210\/jc.2018-00070","journal-title":"J Clin Endocrinol Metab"},{"key":"6144_CR31","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"4","key":"6144_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6(4):275\u2013286. https:\/\/doi.org\/10.1016\/S2213-8587(18)30024-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6144_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R et al (2019) Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 7(5):356\u2013367. https:\/\/doi.org\/10.1016\/S2213-8587(19)30066-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6144_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig A-M, Furberg JK et al (2020) Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 46(2):100\u2013109. https:\/\/doi.org\/10.1016\/j.diabet.2019.101117","journal-title":"Diabetes Metab"},{"issue":"9","key":"6144_CR35","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/dom.14765","volume":"24","author":"M Kellerer","year":"2022","unstructured":"Kellerer M, Kaltoft MS, Lawson J et al (2022) Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab 24(9):1788\u20131799. https:\/\/doi.org\/10.1111\/dom.14765","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6144_CR36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","volume":"23","author":"L Ji","year":"2021","unstructured":"Ji L, Dong X, Li Y et al (2021) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab 23(2):404\u2013414. https:\/\/doi.org\/10.1111\/dom.14232","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"6144_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","volume":"9","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Auerbach P, Bajaj HS et al (2021) Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol 9(9):563\u2013574. https:\/\/doi.org\/10.1016\/S2213-8587(21)00174-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"6144_CR38","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen M-L, Hansen OKH, Jabbour S, Rosenstock J (2017) Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318(15):1460\u20131470. https:\/\/doi.org\/10.1001\/jama.2017.14752","journal-title":"JAMA"},{"issue":"6","key":"6144_CR39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/JDI.14000","volume":"14","author":"T Iijima","year":"2023","unstructured":"Iijima T, Shibuya M, Ito Y, Terauchi Y (2023) Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: a randomized controlled trial. J Diabetes Investig 14(6):774\u2013781. https:\/\/doi.org\/10.1111\/JDI.14000","journal-title":"J Diabetes Investig"},{"issue":"2","key":"6144_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T et al (2018) Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab 20(2):378\u2013388. https:\/\/doi.org\/10.1111\/dom.13082","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6144_CR41","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/DOM.14998","volume":"25","author":"Y Takahashi","year":"2023","unstructured":"Takahashi Y, Nomoto H, Yokoyama H et al (2023) Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: a multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). Diabetes Obes Metab 25(6):1503\u20131511. https:\/\/doi.org\/10.1111\/DOM.14998","journal-title":"Diabetes Obes Metab"},{"issue":"10295","key":"6144_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143\u2013155. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"issue":"10300","key":"6144_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398(10300):583\u2013598. https:\/\/doi.org\/10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet"},{"issue":"10313","key":"6144_CR44","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811\u20131824. https:\/\/doi.org\/10.1016\/S0140-6736(21)02188-7","journal-title":"Lancet"},{"issue":"6","key":"6144_CR45","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327(6):534\u2013545. https:\/\/doi.org\/10.1001\/jama.2022.0078","journal-title":"JAMA"},{"issue":"17","key":"6144_CR46","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/JAMA.2023.20294","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Fr\u00edas JP, Rodbard HW et al (2023) Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA 330(17):1631\u20131640. https:\/\/doi.org\/10.1001\/JAMA.2023.20294","journal-title":"JAMA"},{"issue":"6","key":"6144_CR47","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/S41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, Lee BW, Chawla M et al (2023) Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med 29(6):1500\u20131510. https:\/\/doi.org\/10.1038\/S41591-023-02344-1","journal-title":"Nat Med"},{"issue":"9","key":"6144_CR48","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y (2022) Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 10(9):634\u2013644. https:\/\/doi.org\/10.1016\/S2213-8587(22)00187-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6144_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y (2022) Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10(9):623\u2013633. https:\/\/doi.org\/10.1016\/S2213-8587(22)00188-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10402","key":"6144_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402(10402):613\u2013626. https:\/\/doi.org\/10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"issue":"10160","key":"6144_CR51","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180\u20132193. https:\/\/doi.org\/10.1016\/S0140-6736(18)32260-8","journal-title":"Lancet"},{"key":"6144_CR52","doi-asserted-by":"publisher","first-page":"998816","DOI":"10.3389\/FPHAR.2022.998816","volume":"13","author":"R Guan","year":"2022","unstructured":"Guan R, Yang Q, Yang X, Du W, Li X, Ma G (2022) Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Front Pharmacol 13:998816. https:\/\/doi.org\/10.3389\/FPHAR.2022.998816","journal-title":"Front Pharmacol"},{"issue":"6","key":"6144_CR53","doi-asserted-by":"publisher","first-page":"102511","DOI":"10.1016\/J.DSX.2022.102511","volume":"16","author":"MS Zaazouee","year":"2022","unstructured":"Zaazouee MS, Hamdallah A, Helmy SK et al (2022) Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr 16(6):102511. https:\/\/doi.org\/10.1016\/J.DSX.2022.102511","journal-title":"Diabetes Metab Syndr"},{"key":"6144_CR54","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/J.ECLINM.2023.102181","volume":"64","author":"I Caruso","year":"2023","unstructured":"Caruso I, Di Gioia L, Di Molfetta S et al (2023) Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine 64:102181. https:\/\/doi.org\/10.1016\/J.ECLINM.2023.102181","journal-title":"EClinicalMedicine"},{"key":"6144_CR55","doi-asserted-by":"publisher","first-page":"e074068","DOI":"10.1136\/BMJ-2022-074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi Q, Nong K, Vandvik PO et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381:e074068. https:\/\/doi.org\/10.1136\/BMJ-2022-074068","journal-title":"BMJ"},{"key":"6144_CR56","doi-asserted-by":"publisher","first-page":"107031","DOI":"10.1016\/J.PHRS.2023.107031","volume":"199","author":"Y Ding","year":"2024","unstructured":"Ding Y, Shi Y, Guan R et al (2024) Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. Pharmacol Res 199:107031. https:\/\/doi.org\/10.1016\/J.PHRS.2023.107031","journal-title":"Pharmacol Res"},{"issue":"9","key":"6144_CR57","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/DOM.14775","volume":"24","author":"K Vadher","year":"2022","unstructured":"Vadher K, Patel H, Mody R et al (2022) Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison. Diabetes Obes Metab 24(9):1861\u20131868. https:\/\/doi.org\/10.1111\/DOM.14775","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6144_CR58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/S11892-015-0602-9","volume":"15","author":"D Yabe","year":"2015","unstructured":"Yabe D, Seino Y, Fukushima M, Seino S (2015) \u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep 15(6):36. https:\/\/doi.org\/10.1007\/S11892-015-0602-9","journal-title":"Curr Diab Rep"},{"issue":"6","key":"6144_CR59","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s00125-023-05891-x","volume":"66","author":"A Kautzky-Willer","year":"2023","unstructured":"Kautzky-Willer A, Leutner M, Harreiter J (2023) Sex differences in type 2 diabetes. Diabetologia 66(6):986\u20131002. https:\/\/doi.org\/10.1007\/s00125-023-05891-x","journal-title":"Diabetologia"},{"key":"6144_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.AHJ.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ, Bhatt DL, Buse JB et al (2023) Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J 267:1\u201311. https:\/\/doi.org\/10.1016\/J.AHJ.2023.09.007","journal-title":"Am Heart J"},{"issue":"3","key":"6144_CR61","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/S41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I et al (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28(3):591\u2013598. https:\/\/doi.org\/10.1038\/S41591-022-01707-4","journal-title":"Nat Med"},{"key":"6144_CR62","doi-asserted-by":"publisher","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al (2023) Comparative effectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the US: a real-world evidence study. medRxiv 2023.11.21.23298775 (Preprint). 22 Nov 2023. Available from: https:\/\/doi.org\/10.1101\/2023.11.21.23298775","DOI":"10.1101\/2023.11.21.23298775"},{"issue":"10","key":"6144_CR63","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/S00125-023-05962-Z","volume":"66","author":"T Karagiannis","year":"2023","unstructured":"Karagiannis T, Bekiari E, Tsapas A (2023) Socioeconomic aspects of incretin-based therapy. Diabetologia 66(10):1859\u20131868. https:\/\/doi.org\/10.1007\/S00125-023-05962-Z","journal-title":"Diabetologia"},{"issue":"5","key":"6144_CR64","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/DOM.14979","volume":"25","author":"WJ Valentine","year":"2023","unstructured":"Valentine WJ, Hoog M, Mody R, Belger M, Pollock R (2023) Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes Obes Metab 25(5):1292\u20131300. https:\/\/doi.org\/10.1111\/DOM.14979","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06144-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:03:42Z","timestamp":1717574622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06144-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6144"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06144-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"9 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The datasets generated and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AL has received speaker honoraria and educational support from Novo Nordisk. EB has received research support and speaker honoraria, and has served on an advisory board for Novo Nordisk. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors significantly contributed to the manuscript. TK, AT and EB designed the study. KM, AS, PK, AL, DV, NK and TK contributed to data acquisition. TK, IA and KM did the statistical analysis. TK, AL, DV, NK, AT and EB contributed to interpretation of data. TK wrote the first manuscript draft. All authors edited the final manuscript draft and approved the final version for publication. TK is the guarantor of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}